Compare MOBX & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | BDSX |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 122.0M |
| IPO Year | N/A | 2020 |
| Metric | MOBX | BDSX |
|---|---|---|
| Price | $0.69 | $18.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 97.5M | 150.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | N/A | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.13 | $0.25 |
| 52 Week High | $1.44 | $19.75 |
| Indicator | MOBX | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 73.17 |
| Support Level | $0.67 | $6.33 |
| Resistance Level | $0.92 | N/A |
| Average True Range (ATR) | 0.19 | 1.73 |
| MACD | 0.05 | 0.41 |
| Stochastic Oscillator | 45.28 | 89.10 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.